Manufacturer savings cards for every branded GLP-1, including the new pills: a side-by-side guide — glp1.how · GLP-1 Guides
Manufacturer savings cards for every branded GLP-1, including the new pills: a side-by-side guide
Novo Nordisk and Eli Lilly each run manufacturer copay savings cards for their branded GLP-1s — injectable and oral alike — but the rules, prices, and caps differ by drug, and two programs have quietly been discontinued. Here's every current savings card for Wegovy, Ozempic, Zepbound, Mounjaro, Rybelsus, Trulicity, and the new Foundayo pill side by side, plus what's happened to Saxenda and Victoza.
Updated Aug 31, 2026Evidence-backed
Every branded GLP-1 on the market has, at some point, come with a manufacturer "savings card" promising a copay in the neighborhood of $25. Whether that promise applies to you — and what it's actually worth — depends entirely on which drug you're on, what kind of insurance you have, and whether the program is even still open to new enrollees. Two of the nine cards below have been quietly discontinued, and one is brand new. Here's every current program side by side, sourced from each manufacturer's own site as of August 2026.
Before using any of these, it's worth understanding the mechanism itself — see our savings card glossary entry for what a copay card is and isn't, and manufacturer direct-pay if you have no coverage at all and are pricing out a cash-pay option instead.
Pills are included
Two of the drugs below are swallowed, not injected — Rybelsus (oral semaglutide, approved for diabetes) and Wegovy's own oral tablet (oral semaglutide 25 mg, approved for weight management) both run on the same NovoCare savings programs as their injectable siblings, at the same $25 headline price. And in April 2026, Eli Lilly's Foundayo (orforglipron) became the first non-peptide oral GLP-1 pill — with no food or water restrictions — and launched with its own savings card from day one. All three are in the table and detail sections below alongside the injectables.
Are the GLP-1 pills (Rybelsus, Wegovy tablet, Foundayo) covered by a savings card too, or just the injections?
All three oral GLP-1s have active manufacturer savings cards at the same $25 headline price as the injectables. Rybelsus and the Wegovy oral tablet both run on NovoCare's existing savings programs alongside their injectable siblings, and Foundayo (orforglipron) launched with its own dedicated Lilly savings card when it was FDA-approved in April 2026.
What is Foundayo and how is it different from other GLP-1 pills?
Foundayo (orforglipron) is Eli Lilly's oral GLP-1, FDA-approved in April 2026, and the first one built from a non-peptide small molecule rather than a peptide. That structure means it can be taken any time of day without the food-and-water timing restrictions that apply to Rybelsus. It's available in six dose strengths from 0.8 mg up to 17.2 mg.
Can I use a manufacturer savings card if I have Medicare or Medicaid?
No. Every manufacturer savings card in this guide excludes anyone enrolled in Medicare, Medicaid, TRICARE, VA, DoD, or any other government health program. This is a federal anti-kickback restriction, not a manufacturer choice, and it applies even if you'd pay cash and not bill your government plan at all.
Which GLP-1 savings cards have been discontinued?
Saxenda's savings card has been closed to new enrollees since June 30, 2023, and Victoza's copay card is also closed to new signups and is explicitly excluded from NovoCare's current Diabetes Savings Card. Patients on either drug can look into Novo Nordisk's Patient Assistance Program instead, which uses income-based eligibility rather than an insurance-based copay reduction.
Evidence: For & Against
Both sides of the topic, so you can weigh the evidence yourself.
9Supporting
Improve this page▾
The rules nearly every card shares
Before the drug-by-drug breakdown, five eligibility rules show up on almost every one of these cards. If you remember nothing else, remember these:
Commercial insurance only. Every active card below requires private/employer coverage that includes the drug. None can be used by anyone enrolled in Medicare, Medicaid, TRICARE, VA, DoD, or any other government health program — this is a federal restriction (anti-kickback law), not a manufacturer choice, and it applies even if you'd pay cash and skip billing your government plan entirely.
U.S. residents 18+. All the programs below are restricted to U.S. (Lilly's also include Puerto Rico) residents who are adults.
The card cuts a copay — it doesn't replace coverage. These are copay assistance programs, not insurance. If your plan doesn't cover the drug at all, the card either doesn't apply or switches to a much smaller "non-covered" discount — see each row below.
There's an annual dollar cap, not just a per-fill discount. "As little as $25" is real but capped — once the program has covered its maximum dollar amount for the year, you're back to your normal copay.
Cards expire and get re-issued. Every program below is explicitly time-limited (most run through December 31, 2026) and gets renewed, changed, or discontinued at the manufacturer's discretion. Treat every number here as a snapshot, and confirm current terms before you rely on one.
Not covered by NovoCare's current diabetes savings card
Figures above are illustrative snapshots as of August 2026, not quotes — manufacturers change pricing, caps, and eligibility rules without notice, sometimes mid-year. Always confirm the live terms on the manufacturer's own enrollment page before counting on a number.
Wegovy (semaglutide, Novo Nordisk) — injection and oral tablet
Commercially insured patients whose plan covers Wegovy can pay as little as $25 per month, capped at $100/month in savings — this applies whether you're on the injection or the oral tablet (25 mg), which the FDA approved for weight management in December 2025. If you're uninsured or your plan excludes it, NovoCare Pharmacy's self-pay track has new patients paying $199/month for the 0.25 mg or 0.5 mg injection starting doses (through December 31, 2026), stepping up to $349/month for 0.25–2.4 mg and $399/month for the newer 7.2 mg (Wegovy HD) dose after that. The oral tablet's self-pay tier starts at $149/month for the 1.5 mg starting dose. Enroll at NovoCare.com or by texting SAVE to 83757.
Ozempic (semaglutide, Novo Nordisk)
Ozempic runs on Novo Nordisk's Diabetes Savings Card, alongside Rybelsus. Commercially insured patients pay as little as $25, capped at $100 for a 1-month fill, $200 for a 2-month fill, or $300 for a 3-month fill — through December 31, 2026 for the injection. Self-pay through NovoCare Pharmacy starts new patients at $199/month for the 0.25 mg/0.5 mg doses, then $349/month for 0.25–1 mg and $499/month for 2 mg.
Rybelsus (semaglutide tablets, Novo Nordisk)
Also on the Diabetes Savings Card. Effective January 2, 2026, commercially insured patients on the 3 mg dose pay as little as $25, capped at $100/month; on 7 mg or 14 mg, the same $25 applies with caps of $100/1-month, $200/2-month, or $300/3-month. Unlike some of the other cards, Rybelsus's savings offer stays active for 48 months from the date you activate it, rather than resetting annually. Cash-paying patients cannot use this card — it requires processing through an insurance claim.
Foundayo (orforglipron, Eli Lilly) — the new oral pill
The FDA approved Foundayo in April 2026 as the first oral GLP-1 pill built from a non-peptide molecule, which is why it can be taken any time of day without the food-and-water timing restrictions that apply to Rybelsus. It comes in six doses (0.8, 2.5, 5.5, 9, 14.5, and 17.2 mg tablets). Commercially insured patients whose plan covers it pay as little as $25 for a 1-month or 3-month supply, capped at $100/1-month, $200/2-month, or $300/3-month, with a $1,000 annual maximum and a 10-fill limit — a noticeably tighter annual cap than Zepbound's or Mounjaro's. Uninsured or self-pay patients start at $149/month for the lowest dose, rising to $349/month for the two highest doses ($299/month if refilled on a timely schedule, mirroring LillyDirect's Zepbound vial pricing). Enroll at foundayo.lilly.com.
Zepbound (tirzepatide, Eli Lilly)
Zepbound's card has two tracks depending on whether your plan covers the drug. With coverage, eligible patients pay as little as $25 for a 1-, 2-, or 3-month fill of the single-dose pen, up to 13 fills a year — but Lilly tightened this program for 2026, cutting the monthly savings cap from $150 to $100 and the annual cap from $1,950 to $1,300. Without coverage, the same card discounts the KwikPen to $299–$449/month by dose, or the pen/vial to as low as $499/month. Medicare, Medicaid, TRICARE, and VA patients can't use the commercial card at all, though eligible Medicare Part D beneficiaries may qualify separately for the ~$50/month GLP-1 Bridge demonstration on the Zepbound KwikPen specifically (see our Medicare GLP-1 coverage guide).
Mounjaro (tirzepatide, Eli Lilly)
For type 2 diabetes, prescribed on-label. Commercially insured patients whose plan covers Mounjaro pay as little as $25 per fill, capped at $150/month, $1,950/year, and 13 fills. If your plan doesn't cover it, the same card can bring a 1-month fill down to as low as $499, with a higher monthly savings ceiling (up to $647) reflecting Mounjaro's higher list price (Lilly lists it around $1,080/month). As with every card here, government-insured patients are excluded.
Trulicity (dulaglutide, Eli Lilly)
Eli Lilly's older weekly injectable. Commercially insured patients with Trulicity coverage pay as little as $25 for up to a 3-month fill, capped at $150/1-month, $300/2-month, or $450/3-month, with a $1,950 annual maximum and a 13-fill limit — the same structure as Mounjaro. Enroll at trulicity.lilly.com/savings-resources, by phone, or by texting START to 54559.
Saxenda (liraglutide, Novo Nordisk) — savings card discontinued
Saxenda's manufacturer savings card stopped accepting new enrollees on June 30, 2023, and Novo Nordisk has not reinstated it. If you're already on Saxenda and cost is the obstacle, Novo Nordisk's current guidance points patients toward switching to a GLP-1 that still has an active savings offer — a conversation worth having with your prescriber given that Saxenda's daily dosing and generally more modest weight loss make it a less common first choice today anyway (see our liraglutide guide). Saxenda is also excluded from Novo's Patient Assistance Program, which is built around diabetes medications.
Victoza (liraglutide, Novo Nordisk) — savings card discontinued
Victoza's copay card is likewise closed to new signups, and it's explicitly excluded from NovoCare's current Diabetes Savings Card (which covers only Ozempic and Rybelsus). Existing Victoza patients who are uninsured or underinsured and meet income requirements may still qualify for free medication for up to a year, renewable, through Novo Nordisk's Patient Assistance Program (NovoCare.com or 1-866-310-7549) — a different mechanism from a savings card, with income-based eligibility rather than an insurance-based copay reduction. Our patient assistance program glossary entry explains how PAPs differ from savings cards.
If none of these apply to you
A savings card only helps if you already have commercial insurance that at least partially covers the drug — it can't get you coverage you don't have, and it excludes anyone on a government plan. If a card doesn't apply to your situation, three other paths are usually worth checking:
Price out manufacturer direct-pay. If you have no coverage at all, LillyDirect and NovoCare's self-pay pharmacies sell the same brand product at a flat cash price, which is often cheaper than a capped savings card once you account for the cap.
This is peer information, not medical or financial advice. Savings card prices, caps, and eligibility rules are set unilaterally by each manufacturer and change often — confirm the current terms directly on NovoCare.com, LillyDirect, or the drug's own site before enrolling or budgeting around any figure here.
What's the difference between a savings card and manufacturer direct-pay?
A savings card lowers your copay when you already have commercial insurance that covers the drug, up to a monthly and annual cap. Manufacturer direct-pay (LillyDirect, NovoCare Pharmacy) is a flat cash price for people with no coverage at all — it doesn't touch insurance and is a completely separate mechanism, though both can advertise a similarly low 'as little as $X' headline number.
(external link)
Novo Nordisk (NovoCare) · Reporting · Strong evidence
(2026)
Confirms Ozempic and Rybelsus are covered by this card; Victoza and Saxenda are explicitly not covered.
Related guides
LillyDirect vs. NovoCare: how manufacturer direct-pay actually works — Both GLP-1 makers now sell their own brand medications straight to cash-paying patients — Lilly through LillyDirect, Novo Nordisk through NovoCare. Here's what these direct-pay channels actually are, how single-dose vials differ from pens, how a flat cash price differs from a savings card, and the problems direct-pay doesn't solve.
How to determine if your insurance formulary covers GLP-1 medications — Before you can get a GLP-1 medication covered, you need to know if it's on your plan's formulary — and where. Here's how to check, what the tiers mean, and who actually decides what's on the list in the first place.
Understanding insurance coverage for GLP-1 medications — Coverage for GLP-1 medications hinges on three levers — formulary, prior authorization, and step therapy — plus a fourth most people miss: whether the prescription is for diabetes or weight management. Here's how each actually works, and how to build your best case for coverage.
How compounded GLP-1 medications are made — and how that differs from the branded pens — A compounded GLP-1 isn't a knockoff pen off a production line — it's mixed from raw active ingredient at a pharmacy. Here's how the drug substance is sourced, how the formula and dose are set, how a sterile compounding pharmacy actually makes the vial, and how all of that compares with the tightly controlled, FDA-approved process behind Ozempic, Wegovy, and Zepbound.
How to verify a pharmacy is legitimate: BeSafeRx, NABP, and your state board — Our sourcing guides keep ending on the same instruction — verify the pharmacy with your state board, the NABP, or FDA's BeSafeRx — without saying how. This is the step-by-step: the free tools each one offers, what red flags to look for, how to pull a pharmacy's license record, and how to check your own pen's lot number against FDA's counterfeit alerts. About five minutes, start to finish.